Evaluate Omnium

Evaluate Omnium provides a complete, dynamic view of development risk and commercial return across all phases of the clinical lifecycle — including early-phase and privately-developed drugs not covered by analysts forecasts.

With product-specific data included Predicted Peak Sales, Probability of Technical and Regulatory Success (PTRS), R&D Costs, Net Present Value, Time-to-Peak and more, Evaluate Omnium makes it easier than ever quantify and compare risk and return across the full pipeline landscape.

Explore the video and other content below to see how Evaluate Omnium transforms asset screening and valuation, competitive intelligence, portfolio prioritisation and internal forecasting, then request your free trial today.

80% of R&D drugs aren't covered by analyst forecasts until Phase III, so how can you make informed, objective decisions about a product's future in earlier phases?

Predicted Peak Sales analyses 25 years of market data and 4.3m data points to predict commercial potential from Phase I. It covers 99% of NMEs in our system, while delivering 53% more accuracy than consensus forecasts for early-stage drugs and comparable accuracy for late-stage drugs.

Watch the video to learn more about how Predicted Peak Sales delivers the coverage you need — with numbers you can trust.

With 88% of novel drugs failing in clinical development, inaccurate risk assessments cost the industry billions in wasted R&D spending every year.

Evaluate Omnium's Product Specific PTRS analyses over 1.7m data points, 37,000 phase transitions and 26,000 drug programmes to predict a drug’s individual risk based on 50+ unique product attributes. As a result, it delivers 4 times greater accuracy when predicting which Phase I assets will reach the market, compared to industry average benchmarks.

Alongside historic success rates, phase progression probabilities and detailed risk audits, Product Specific PTRS provides the insight and context need to fully understand which drugs have the greatest potential to reach the market, so you can make more informed strategic choices.

With the range and scope of data available across Evaluate Omnium, it's never been easier to explore risk and return in a single, combined view. 

Evaluate Omnium's exclusive data visualisations allow you compare the Predicted Peak Sales and Product Specific PTRS for each product in the market landscape, so you can instantly determine which drugs have the best chance of market approval and success. In addition, the integrated data makes it easy to drill down and understand the unique factors driving each product's predictions.

The average cost of bringing a new drug to market can reach $1.6bn, so it's critical to understand whether the potential value is worth the investment.

Evaluate Omnium's Net Present Value (NPV) Analyzer offers a detailed, standardised view of the current NPV for over 6,000 products, based on discounted cash flow models to 2040. Fully transparent and interactive, you can quickly view the data inputs, or edit to create custom predictive models.

NPV by Indication adds another level of granularity, extending the NPV Analyzer model to the indication level for improved understanding of product value drivers. 

It's no secret that Pharma R&D is costly, but it can be almost impossible to access independent, granular data on the level of investment needed to bring a drug to market.

Evaluate Omnium's R&D Costs delivers the industry’s first comprehensive clinical trial costing model, providing product- and trial-level costs in more detail than ever before. By applying real-world data to over 50,000 trials, R&D Costs provides estimated spending for all past and current clinical trials, as well as future cost predictions by phase.

Get the insight you need to compare relative product development costs, determine whether product returns justify future investments or benchmark your R&D productivity against competitors.